SCHEMBL2238528

SCHEMBL2238528

COc1cccc(-c2cncc(-c3cc(NC4CC4)nc(-c4ccccn4)n3)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.50
TDP1 Q9NUW8 1/20 0.50
NPC1 O15118 1/20 0.47
PKM P14618 1/20 0.47
GRM5 P41594 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CLK4 Q9HAZ1 4/20 0.45
CYP2C19 P33261 3/20 0.45
ALDH1A1 P00352 3/20 0.45
LMNA P02545 3/20 0.45
CYP3A4 P08684 3/20 0.45
ALOX15 P16050 3/20 0.45
TSHR P16473 3/20 0.45
MAPK1 P28482 3/20 0.45
USP2 O75604 2/20 0.45
CYP2D6 P10635 2/20 0.45
TP53 P04637 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4175691 0.87 CYP1A2 (0.46) CYP1A2TDP1NPC1PKMGRM5
SCHEMBL2238727 0.87 NPC1 (0.52) CYP1A2NPC1PKMGRM5RAB9A
SCHEMBL2239406 0.84 FFAR1 (0.54) CYP1A2NPC1PKMGRM5RAB9A
SCHEMBL2237625 0.82 CLK4 (0.59) CYP1A2TDP1NPC1PKMGRM5
SCHEMBL3661108 0.81 NPC1 (0.54) CYP1A2NPC1PKMGRM5RAB9A
SCHEMBL2238718 0.79 FFAR1 (0.54) NPC1PKMGRM5RAB9ASMN1; SMN2
SCHEMBL2240058 0.78 HIF1A (0.51) CYP1A2TDP1NPC1PKMGRM5
SCHEMBL2241190 0.78 KDM4E (0.46) NPC1PKMGRM5RAB9ASMN1; SMN2
SCHEMBL2240891 0.77 NPC1 (0.48) TDP1NPC1PKMGRM5RAB9A
SCHEMBL3659157 0.76 FFAR1 (0.48) CYP1A2NPC1PKMGRM5RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP claimed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US claimed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US claimed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP claimed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO claimed
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP disclosed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US disclosed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US disclosed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP disclosed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors ALK, ACVR1, MUSK CYP1A2 929/4885TDP1 752/4885NPC1 3942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.